Balyasny Asset Management
VYNE icon

Balyasny Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Balyasny Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-165
Closed -$96K – 2070
2018
Q2 		$96K Buy
+165
New +$128K ﹤0.01% 1710

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management's VYNE Position: Q3 2018 in Review

Balyasny Asset Management sold out of VYNE Therapeutics (VYNE) in Q3 2018, closing a stake of 165 shares — an estimated $96K sold.

Balyasny Asset Management first reported a position in VYNE in Q2 2018 and held it in 1 quarter. The position peaked at $96K in Q2 2018. 52 funds tracked by Wall St. Rank hold VYNE as of Q3 2018.

  • Balyasny Asset Management reported no remaining VYNE Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 165 VYNE Therapeutics shares in Q3 2018, an estimated $96K.
  • Balyasny Asset Management first reported a position in VYNE Therapeutics in Q2 2018 and held it in 1 quarter.
  • Balyasny Asset Management's VYNE Therapeutics position peaked at $96K in Q2 2018.
  • 52 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.